Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …

Background Use of chemotherapy near the end of life in patients with metastatic cancer is
often ineffective and toxic. Data about the factors associated with its use remain scarce, …

Endometrial cancer (EC) can easily be cured when diagnosed at an early stage. However,
advanced and metastatic EC is a common disease, affecting more than 15,000 patients per …

Natural killer (NK) cells are major antileukemic immune effectors. Leukemic blasts have a
negative impact on NK cell function and promote the emergence of phenotypically and …

… Rochigneux reports serving as speaker/board for Novartis, AstraZeneca, and Viatris, and
receiving travel expenses from Pfizer. Tagliamento reports receiving travel grants from Roche, …

Objective To investigate patterns of care during the last months of life of hospitalised
patients who died from different haematological malignancies. Methods Nationwide register-based …

Simple Summary The mortality of hepatocellular carcinoma (HCC) is quickly increasing
worldwide. Immunotherapy enables the immune defense of the organism to target liver cancer …

The 5-year survival rate of primary anorectal malignant melanoma is less than 20%. Optimal
treatment of this condition remains controversial regarding locally disease, and whether any …

… Philippe Rochigneux… Philippe Rochigneux , Jean-Charles Nault, Françoise Mallet,
Anne-Sophie Chretien, Nathalie Barget, Alejandro J. Garcia, Lucie Del Pozo, Valérie Bourcier …

An imbalance between effector CD8 + T cells and CD25 high effector Tregs marks
immunosuppressive microenvironments in αPD-1–resistant TNBC and can be reversed through …